Quick Summary
This review summarizes what scientists and doctors know about fibromyalgia and ME/CFS by examining research from the past 25 years. The authors looked at studies on symptoms, causes, blood test findings, brain imaging, and what patients reported about their experiences. They propose that these conditions may need to be understood in an entirely new way.
Why It Matters
This comprehensive review helps establish that ME/CFS and fibromyalgia are recognized medical conditions with measurable biological abnormalities—not psychological disorders. By consolidating multiple lines of evidence, it provides a foundation for understanding these conditions and supporting the need for new research directions and treatment approaches.
Observed Findings
What the study reports it measured.
- Multiple biochemical abnormalities have been documented in fibromyalgia and ME/CFS patients
- Neuroimaging studies reveal measurable abnormalities in affected individuals
- Functional neurophysiologic testing shows abnormal patterns in these patient populations
- Comorbid conditions frequently occur alongside fibromyalgia and ME/CFS
- Microbiologic abnormalities have been identified in some patient cohorts
Inferred Conclusions
What the authors interpret from those results.
- Fibromyalgia and ME/CFS represent distinct biological disorders with demonstrable physiological abnormalities, not psychosomatic conditions
- Current understanding of these conditions is limited and requires a fundamentally new conceptual framework
- Integration of biological data with patient-reported experiences is essential for comprehensive understanding
Remaining Questions
- What is the primary biological mechanism driving these conditions?
- Are fibromyalgia and ME/CFS distinct entities or variations of the same disorder?
- Which specific biomarkers best predict disease severity and treatment response?
- What role do microbiologic factors play in pathogenesis?
What This Study Does Not Prove
This review does not establish the specific causes of ME/CFS or fibromyalgia, nor does it prove that any single biomarker definitively explains these syndromes. As a synthesis of existing literature rather than a primary research study, it cannot prove causation for any proposed mechanisms and does not replace controlled clinical trials.
Explore further
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Cite this study
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Mehendale, Anand W & Goldman, Mark P (2002). Fibromyalgia syndrome, idiopathic widespread persistent pain or syndrome of myalgic encephalomyelopathy (SME): what is its nature?. Pain practice : the official journal of World Institute of Pain. https://doi.org/10.1046/j.1533-2500.2002.02003.x
BibTeX
@article{mecfsatlas-mehendale-2002-fibromyalgia-syndrome,
author = {Mehendale, Anand W and Goldman, Mark P},
title = {Fibromyalgia syndrome, idiopathic widespread persistent pain or syndrome of myalgic encephalomyelopathy (SME): what is its nature?},
journal = {Pain practice : the official journal of World Institute of Pain},
year = {2002},
doi = {10.1046/j.1533-2500.2002.02003.x},
note = {PubMed: 17134468},
url = {https://www.mecfsatlas.com/evidence/mehendale-2002-fibromyalgia-syndrome},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/mehendale-2002-fibromyalgia-syndrome
Contribute
Private, reviewed by a human. Not a public comment thread.